Haemophilia Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), By Products (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin and Antifibrinolytic Agents), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Region

Haemophilia Treatment Market size was valued at US$ 9,834.7 million in 2023 and is projected to reach US$ 15,387.3 million by 2030, growing at a 5.2% CAGR from 2024 to 2030. Hemophilia is an inherited bleeding disorder that is caused by the lack of clotting proteins, a patient suffering from hemophilia bleeds longer than usual or even bleeds internally. The primary treatment for is to replace the missing clotting factor through intravenous infusion. The rising prevalence of hemophilia across the world and technological advancement in medications drive market growth.

According to the Centres for disease control and Prevention, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia, each year, as many as 33,000 males in the United States are living with the disorder. The growing adoption of prophylaxis treatment and the upsurge of hemophilia prevalence in newborns enhance the market growth. The government initiatives for the promotion of hemophilia treatment and increase in research and development on identifying therapeutic agent consequences lucrative opportunities in the market. The increased cost of medications and rising adverse reactions of plasma treatment products are the major factors limiting market growth.

Key Developments

• In February 2023, The U.S. Food and Drug Administration (FDA) approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy.
• In May 2022, Takeda launched Adynovate for the prophylaxis treatment of hemophilia patients in India. Adynovate, combined with MYPKFIT, the first and only FDA-approved application, offers personalized and interactive prophylaxis treatment options.